A year after attempting to partner with French drug maker Sanofi – only to have US regulators stop the deal over antitrust concerns – Maze Therapeutics has entered into a similar partnership with Shionogi & Co. Ltd.for the oral Pompe disease drug MZE001.
The companies announced the exclusive worldwide collaboration on 10 May, whereby Shionogi will pay Maze $150m up front, plus undisclosed milestone payments based on development, regulatory and commercial achievements, along...
Key Takeaways
-
Shionogi reached out to Maze and made a deal for an exclusive global license for MZE001 in Pompe disease.
-
The deal includes a $150m...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?